Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
alflutinib (6 trials)
furmonertinib (6 trials)
gefitinib (iressa) (1 trial)
anlotinib (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Lung Neoplasms (Phase 3)
Trials (12 total)
Trial APIs (4 total)